US Oncology acquires CURE Media Group and NexCura

NewsGuard 100/100 Score

US Oncology, Inc., the premier cancer care services organization supporting the nation's largest cancer treatment and research network dedicated to advancing the quality and cost-effectiveness of cancer care in America, announced today that it has acquired Dallas-based CURE Media Group and Seattle-based NexCura. These two companies serve as an important piece of the overall strategy for US Oncology to expand the availability of integrated and personalized information and resources on specific diseases and treatments to cancer patients in America.

CURE Media Group publishes CURE magazine and its associated Website www.curetoday.com. With a mission to make cancer easier to understand for patients, CURE magazine and the curetoday.com Website each provide rich, patient-focused content regarding all aspects of cancer care, research, and other patient issues. The magazine is a free, advertiser-supported quarterly publication designed to provide cancer patients with the necessary resources to help them throughout their journey with cancer. The magazine offers special editions and organizes live events such as the Oncology Nursing Society's Extraordinary Healer award event that brings together patients and caregivers.

NexCura is an online resource that provides timely and targeted knowledge for patients and caregivers facing critical treatment choices. Patients using NexCura's patented Cancer Profiler technology generate reports of individualized treatment options based on peer-reviewed clinical research. NexCura tools cover 85% of all cancers. The NexCura tool is free for patients and is distributed through placement on various premier Websites such as the American Cancer Society website www.cancer.org and the LIVESTRONG website www.livestrong.org.

Starting in May of this year, both www.curetoday.com and the NexCura Profiler technology will be available to all patients in the United States through the US Oncology Website, www.usoncology.com, and through other Websites. As is true with all US Oncology affiliations, CURE Media Group and NexCura will remain operationally and editorially independent, but will be able to tap into US Oncology resources to expand distribution and presence to reach more patients in America.

"The tools available through CURE and NexCura will enhance US Oncology's multi-channel strategy to give patients round-the-clock access to their personal health record, enable them to be better informed about their particular disease, and provide resources to help patients manage their care online," says Bruce Broussard, Chairman and CEO of US Oncology. "We envision enhancing our integrated care model by developing virtual connectivity of care providers and patients through these new resources."

"These acquisitions demonstrate a commitment to a key strategic focus of empowering patients with integrated and personalized information and resources for cancer care," says Roy Beveridge, M.D., Medical Director at US Oncology. "With the addition of CURE Media Group and NexCura, US Oncology now has the ability to service patients in person through its 493 sites of service, in print through CURE magazine, and online through www.curetoday.com and NexCura's treatment decision tools."

SOURCE US Oncology, Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Revolutionizing brain tumor treatment: the rise of AI in neuro-oncology